Introdução: A obesidade é um importante problema de Saúde Pública e, segundo a Organização Mundial da Saúde, representa uma epidemia global. É considerada uma doença crônica, multifatorial, que depende não só de fatores genéticos e fisiopatológicos, mas também de variáveis culturais, sociais e psicológicas associadas à quantidade e a qualidade da alimentação. Nesse contexto, os adolescentes como foco de mudanças fisiológicas, anatômicas e sociais se tornam um grupo com elevada frequência de fatores de risco associados à obesidade. Objetivo: Avaliar o papel da lipoproteína de baixa densidade eletronegativa [LDL(-)], da proteína transportadora de éster de colesterol (CETP) e da resistência à insulina (RI) no risco cardiometabólico de adolescentes. Métodos: Foram recrutados adolescentes de ambos os sexos, com faixa etária de 10 a 19 anos e, regularmente matriculados em escolas da cidade de São Paulo. Medidas antropométricas, tais como, peso, altura, circunferência da cintura (CC) e composição corporal foram avaliadas, e classificadas considerando sexo e idade. Após jejum (12-15h), foi coletada uma amostra de sangue e a partir do plasma foram realizadas as seguintes análises: glicose, insulina e cálculo do HOMA, perfil lipídico, apolipoproteína A-I e B, atividade da paraoxonase 1 (PON1), ácidos graxos livres (AGL), atividade da CETP e LDL(-). Os resultados obtidos foram analisados por meio dos testes qui-quadrado, Kappa, Kolmogorov-Smirnov, t-student, ANOVA, Mann-Whitney, Kruskal-Wallis, Bonferroni e de tendência linear, com valor de significância de p< 0,05. Resultados: Os adolescentes eutróficos apresentaram menor atividade de CETP e conteúdo de LDL(-) em relação àqueles com excesso de peso. O IMC apresentou associação positiva e linear com o CT/HDL-C, TG/HDL-C, ApoB/ApoA-I, LDL(-) e LDL(-)/CT. Perfil inverso foi observado para HDL-C e ApoA-I. A CC mostrou associação positiva com TG, CT/HDL-C, LDL-C/HDL-C, TG/HDL-C, ApoB/ApoA-I, LDL(-), LDL(-)/CT e CETP. Associação negativa foi observada entre CC e HDL-C e ApoA-I. Após o ajuste pela atividade da CETP, associações entre o HDL-C, LDL-C/HDL-C, CT/HDLC e LDL(-)/LDL-C com o IMC ou CC foram modificadas. Ao ajustarmos pela concentração de LDL(-), nenhuma associação sofreu alteração, o que sugere um mecanismo independente para a regulação dessa partícula durante a obesidade.Ao analisarmos os adolescentes segundo CC, verificamos que os adolescentes com CCALTA apresentaram elevado IMC, por cento de gordura corporal, pressão arterial sistólica, conteúdo de insulina, HOMA, TG, TG/HDL-C, CT/HDL-C, LDL-C/HDL-C, ApoB/ApoA-I, AGL, LDL(-), LDL(-)/CT e atividade da CETP, quando comparados aqueles com CCBAIXA. Perfil inverso foi observado para por cento de massa magra, HDL-C, ApoA-I, HDL/ApoA-I e PON-1. Quando classificados segundo HOMA (resistente à insulina - RI e sensível à insulina - SI), os adolescentes RI mostraram um impacto negativo sobre o IMC, CC, por cento de gordura corporal, pressão arterial, TG e TG/HDL-C, e resultado inverso para por cento de massa magra e PON1. O índice de risco cardiovascular proposto mostrou que o grupo CCALTA-RI = CCALTA-SI > CCBAIXA-RI = CCBAIXASI. Conclusões: Portanto, a concentração de LDL(-) e a atividade da CETP associada à obesidade, principalmente abdominal, alteram o risco cardiometabólico de adolescentes / Introduction: Obesity is a major public health problem and, according to World Health Organization, represents a global epidemic. It is considered a chronic, multifactorial disease, which depends not only of genetic and pathophysiology factors, but also of cultural, social and psychological associated with diet profile variables. In this context, adolescents as the focus of physiological, anatomical and social changes become a group with high frequency of risk factor for obesity. Objective: To evaluate the role of the electronegative low-density lipoprotein [LDL(-)] concentration, cholesteryl ester transfer protein (CETP) activity and insulin resistance on cardiometabolic risk of adolescents. Methods: We recruited adolescents of both sexes, aged 10 to 19 years and enrolled in schools in the city of São Paulo. Anthropometric measurements such as weight, height, waist circumference (WC) and body composition were evaluated and classified according to sex and age. After fasting (12-15h) was analyzed from plasma: glucose, insulin and HOMA, lipid profile, apolipoprotein A-I and B, paraoxonase 1 activity (PON1), non-esterified fatty acids (NEFA), CETP activity and LDL(-). The results were analyzed by chi-square, Kappa, Kolmogorov-Smirnov, t-student, ANOVA, Mann-Whitney, Kruskal-Wallis, Bonferroni and linear tendency test, with p< 0.05. Results: The subjects with normal weight had lower CETP activity and content of LDL(-) than excess weight adolescents. BMI showed positive and linear association with TC/HDL-C, TG/HDL-C, ApoB/ApoA-I, LDL(-) and LDL(-)/TC. Profile opposite was observed for HDL-C and ApoA-I. The WC was positively associated with TG, TC/HDL-C, LDL-C/HDL-C, TG/HDL-C, ApoB/ApoA-I, LDL(-), LDL(-)/CT and CETP. Negative association was observed between WC and HDL-C and ApoA-I. After adjustment for CETP, associations between HDL-C, LDL-C/HDL-C, TC/HDL-C and LDL(-)/LDL-C with BMI or WC were modified. Adjustment for LDL(-) content was not able to change these associations, suggesting an independent mechanism for regulation of the levels of this particle during obesity. Analysis second WC, it was found that adolescents 10 with WCHIGH showed higher BMI, per cent body fat, systolic blood pressure, insulin, HOMA, TG, TG/HDL-C, TC/HDL-C, LDL-C/HDL-C, ApoB/ApoA-I, NEFA, LDL(-), LDL(-)/TC and CETP activity than WCLOW group. Profile opposite was observed for per cent lean body mass, HDL-C, ApoA-I, HDL/ApoA-I and PON-1. When it classified according to HOMA (insulin resistant IR and insulin sensitive IS), IR group showed a negative impact on BMI, WC, per cent body fat, blood pressure, TG and TG/HDL-C, and contrary result for per cent mass lean and PON1. The cardiovascular risk index propose showed that WCHIGH IR = WCHIGH IS > WCLOW IR = WCLOW IS group. Conclusions: Therefore, LDL(-) content and CETP activity associated with obesity, mainly abdominal, alter the cardiometabolic risk of adolescents

Introdução: A prática de caminhada é recomendada como principal tratamento de indivíduos com claudicação intermitente (CI). Contudo, a realização da caminhada é acompanhada de dor. Tendo em vista que indivíduos com CI apresentam redução de força e massa musculares, é possível que o treinamento de força seja eficaz para o tratamento desses indivíduos. Objetivo: Verificar os efeitos do treinamento de força na aptidão física e em indicadores de qualidade de vida de indivíduos com CI. Métodos: Os indivíduos (n=42), recrutados no Ambulatório de Claudicação Intermitente do Hospital das Clínicas da Universidade de São Paulo, foram distribuídos em três grupos: treinamento de força (GTF), treinamento de caminhada (GCA) e controle (GCO); que foram submetidos a 12 semanas de treinamento físico. O GTF e o GCA realizaram treinamento supervisionado, em duas sessões semanais de 60 minutos cada. O GCO realizou treinamento não supervisionado. Antes e após o treinamento, foram mensurados componentes da aptidão física (massas gordurosa e magra, índice de massa muscular, distâncias de claudicação e total de caminhada, capacidade aeróbica, força muscular de membros inferiores, índice tornozelo braço, janela isquêmica, pressão arterial de braço, freqüência cardíaca e duplo produto) e indicadores da qualidade de vida (geral e capacidade de deambulação). Para os dados paramétricos foram utilizadas Análise de Variância e de Covariância, e para os dados não paramétricos, foram utilizados os testes de Wilcoxon e Kruskall- Wallis, com P<0,05. Resultados: O treinamento de força aumentou as distâncias de claudicação (+40,8%) e total de caminhada (+25,4%) e a força muscular dos membros inferiores, com maior, e menor índice tornozelo-braço (+9,5% e +10,5%, respectivamente). Foi observada redução da janela isquêmica (-46,9%), da freqüência cardíaca (-6,5%) e do duplo produto (- 15,9%) em repouso, e da pressão arterial de braço (-8,1%) e do duplo produto (-9,8%) em exercício sub-máximo. As modificações na aptidão física no GTF foram semelhantes aquelas observadas no GCA. Não foram observadas alterações nos indicadores de qualidade de vida após o treinamento de força. Conclusão: Os resultados deste estudo sugerem que o treinamento de força pode ser incorporado ao tratamento clínico dos indivíduos com CI, uma vez que promoveu melhoria nos componentes da aptidão física desta população. / Abstract Background: Walking exercise training has been recommended as the main treatment in persons with intermittent claudication (IC). However, walking is performed with pain. Once persons with IC present muscle atrophy and reduced leg strength, strength training programs could be successful in the treatment of these patients. Objective: To verify the effects of strength training on physical fitness and indicators of quality of life in persons with IC. Methods: Forty two subjects were recruited in the Intermittent Claudication Ambulatory of Clinics Hospital of the University of Sao Paulo. The subjects were allocated into three groups: strength training (ST), treadmill training (TT) and control (CO); which performed 12 weeks of exercise training. ST and TT performed supervised exercise, twice a week, in 60-minute sessions. CO performed unsupervised training. Before and after training, the components of physical fitness (fat and lean body mass, muscle mass index, claudication and total walking distances, leg strength, ankle brachial index, ischemic window, arm blood pressure, heart rate and rate pressure product) and quality of life indicators (general and related with ambulation capacity), were assessed. Analysis of Variance and Analysis of Covariance were used for parametric data; Wilcoxon and Kruskall-Wallis tests were used for non-parametric data, with P<0.05 Results: ST increased claudication (+40.8%) and total walking distances (+25.4%), and strength in the leg with higher and with lower ankle brachial index (+9.5 and +10.5%, respectively). There were a decrease in ischemic window (-46.9%), rest heart rate (-6.5%) and rate pressure product (-15.9%), and submaximal arm blood pressure (-8.1%) and rate pressure product (-9.8%). The changes in physical fitness were similar between ST and TT. There were no changes in the quality of life indicators after ST. Conclusions: The results of the present study suggest that ST could be used in the treatment of persons with IC, once it can improve the physical fitness in these patients.

INTRODUÇÃO: As doenças cardiovasculares (DCV) são a principal causa de morte no mundo, sendo muitos dos fatores de risco passíveis de prevenção e controle. Embora as DCV sejam complexas em sua etiologia e desenvolvimento, a concentração elevada de LDL-c e baixa de HDL-c constituem os fatores de risco modificáveis mais monitorados na prática clínica, embora não sejam capazes de explicar todos os eventos cardiovasculares. Portanto, investigar como intervenções farmacológicas e nutricionais podem modular parâmetros oxidativos, físicos e estruturais das lipoproteínas pode fornecer estimativa adicional ao risco cardiovascular. Dentre os diversos nutrientes e compostos bioativos relacionados às DCV, os lipídeos representam os mais investigados e descritos na literatura. Nesse contexto, os ácidos graxos insaturados (ômega-3, ômega-6 e ômega-9) têm sido foco de inúmeros estudos. OBJETIVOS: Avaliar o efeito da suplementação com ômega-3, ômega-6 e ômega-9 sobre os parâmetros cardiometabólicos em indivíduos adultos com múltiplos fatores de risco e sem evento cardiovascular prévio. MATERIAL E MÉTODOS: Estudo clínico, randomizado, duplo-cego, baseado em intervenção nutricional (3,0 g/dia de ácidos graxos) sob a fórmula de cápsulas contendo: ômega-3 (37 por cento de EPA e 23 por cento de DHA) ou ômega-6 (65 por cento de ácido linoleico) ou ômega-9 (72 por cento de ácido oleico). A amostra foi composta por indivíduos de ambos os sexos, com idade entre 30 e 74 anos, apresentando pelo menos um dos seguintes fatores de risco: Dislipidemia, Diabetes Mellitus, Obesidade e Hipertensão Arterial Sistêmica. Após aprovação do Comitê de Ética, os indivíduos foram distribuídos nos três grupos de intervenção. No momento basal, os indivíduos foram caracterizados quanto aos aspectos demográficos (sexo, idade e etnia) e clínicos (medicamentos, doenças atuais e antecedentes familiares). Nos momentos basal e após 8 semanas de intervenção, amostras de sangue foram coletadas após 12h de jejum. A partir do plasma foram analisados: perfil lipídico (CT, LDL-c, HDL-c, TG), apolipoproteínas AI e B, ácidos graxos não esterificados, atividade da PON1, LDL(-) e auto-anticorpos, ácidos graxos, glicose, insulina, tamanho e distribuição percentual da LDL (7 subfrações e fenótipo A e não-A) e HDL (10 subfrações). O efeito do tempo, da intervenção e associações entre os ácidos graxos e aspectos qualitativos das lipoproteínas foram testados (SPSS versão 20.0, p <0,05). RESULTADOS: Uma primeira análise dos resultados baseada em um corte transversal demonstrou, por meio da análise de tendência linear ajustada pelo nível de risco cardiovascular, que o maior tercil plasmático de DHA se associou positivamente com HDL-c, HDLGRANDE e tamanho de LDL e negativamente com HDLPEQUENA e TG. Observou-se também que o maior tercil plasmático de ácido linoleico se associou positivamente com HDLGRANDE e tamanho de LDL e negativamente com HDLPEQUENA e TG. Esse perfil de associação não foi observado quando foram avaliados os parâmetros dietéticos. Avaliando uma subamostra que incluiu indivíduos tabagistas suplementados com ômega-6 e ômega-3, observou-se que ômega-3 modificou positivamente o perfil lipídico e as subfrações da HDL. Nos modelos de regressão linear ajustados pela idade, sexo e hipertensão, o DHA plasmático apresentou associações negativas com a HDLPEQUENA. Quando se avaliou exclusivamente o efeito do ômega-3 em indivíduos tabagistas e não tabagistas, observou-se que fumantes, do sexo masculino, acima de 60 anos de idade, apresentando baixo percentual plasmático de EPA e DHA (<8 por cento ), com excesso de peso e gordura corporal elevada, apresentam maior probabilidade de ter um perfil de subfrações de HDL mais aterogênicas. Tendo por base os resultados acima, foi comparado o efeito do ômega-3, ômega-6 e ômega-9 sobre os parâmetros cardiometabólicos. O ômega-3 promoveu redução no TG, aumento do percentual de HDLGRANDE e redução de HDLPEQUENA. O papel cardioprotetor do ômega-3 foi reforçado pelo aumento na incorporação de EPA e DHA, no qual indivíduos com EPA e DHA acima de 8 por cento apresentaram maior probabilidade de ter HDLGRANDE e menor de ter HDLPEQUENA. Em adição, observou-se também que o elevado percentual plasmático de ômega-9 se associou com partículas de LDL menos aterogênicas (fenótipo A). CONCLUSÃO: Ácidos graxos plasmáticos, mas não dietéticos, se correlacionam com parâmetros cardiometabólicos. A suplementação com ômega-3, presente no óleo de peixe, promoveu redução no TG e melhoria nos parâmetros qualitativos da HDL (mais HDLGRANDE e menos HDLPEQUENA). Os benefícios do ômega-3 foram particularmente relevantes nos indivíduos tabagistas e naqueles com menor conteúdo basal de EPA e DHA plasmáticos. Observou-se ainda que o ômega-9 plasmático, presente no azeite de oliva, exerceu impacto positivo no tamanho e subfrações da LDL. / INTRODUCTION: Cardiovascular diseases (CVD) are the leading cause of death worldwide and many of the risk factors are likely to prevention and control. While CVD are complex in their etiology and development, a high concentration of LDL-c and low HDL-c are the most investigated modifiable risk factors in clinical practice, although they are not able to explain all cardiovascular events. So investigate how nutritional and pharmacological interventions can modulate oxidative, physical and structural parameters of lipoproteins can provide additional estimate for cardiovascular risk. Among the many nutrients and bioactive compounds related to CVD, lipids represent the most investigated and described in the literature. In this context, the unsaturated fatty acids (omega-3, omega-6 and omega-9) have been focus of numerous studies. OBJECTIVES: To evaluate the effect of supplementation with omega-3, omega-6 and omega-9 on cardiometabolic parameters in adults with multiple risk factors and without previous cardiovascular event. MATERIAL AND METHODS: Clinical trial, randomized, double-blind, based on nutritional intervention (3.0 g/day of fatty acids) containing: omega-3 (37 per cent EPA and 23 per cent DHA) or omega-6 (65 per cent linoleic acid) or omega-9 (72 per cent of oleic acid). Subjects of both sexes, aged between 30 and 74 years old, with at least one of the following risk factors: hyperlipidemia, diabetes mellitus, obesity and hypertension were included. After Ethics Committee approval, the subjects were distributed on the three intervention groups. At baseline the demographic (gender, age and ethnicity) and clinical (medications, current diseases and family history) data were evaluated. At baseline and after 8 weeks of intervention, blood samples were collected after 12 hours of fasting. From the plasma were analyzed: lipid profile (TC, LDLc, HDL-c, TG), apolipoproteins AI and B, non esterified fatty acid, PON1 activity, LDL (-) and autoantibodies, fatty acids, glucose, insulin, size and distribution of LDL (7 subfractions and phenotype) and HDL (10 subfractions). The effect of time, intervention and associations between fatty acids and qualitative aspects of lipoproteins were evaluated (SPSS version 20.0, p <0.05). RESULTS: A first analysis of the results based on a cross sectional study showed through the linear trend analysis, adjusted by the level of cardiovascular risk, that the highest tertile of plasma DHA was positively associated with HDL-c, HDLLARGE and LDL size and inversely with HDLSMALL and TG. The highest tertile of plasma linoleic acid was positively associated with HDLLARGE and LDL size and negatively with HDLSMALL and TG. This association was not observed when we evaluated the dietary parameters. A sample including smokers supplemented with omega-6 and omega-3 showed that omega-3 positively modify the lipid profile and HDL subfractions. In linear regression models adjusted for age, sex and hypertension, plasma DHA showed negative associations with HDLSMALL. When only assessed the effect of omega-3 in smokers and non-smokers, the results showed that smokers, male, over 60 years old, with low percentage of EPA and DHA (<8 per cent ), overweight and/or obese and high body fat have an increased chance to have HDL subfractions profile less cardioprotective. Based on the above results, we compared the effect of omega-3, omega-6 and omega-9 on cardiometabolic parameters. The omega-3 decreased TG, increase the percentage of HDLLARGE and decrease HDLSMALL. The cardioprotective role of the omega-3 was enhanced by increasing the incorporation of EPA and DHA, in which subjects with more than 8 per cent of EPA and DHA were more likely to have HDLLARGE and lower HDLSMALL. In addition, it was also observed that higher omega-9 plasma levels was associated with less atherogenic LDL particles (phenotype A). CONCLUSION: Plasma fatty acids, but not dietary, correlate with cardiometabolic parameters. Supplementation with omega-3, present in fish oil, promoted reduction in TG and improved the qualitative parameters of HDL (more HDLARGE and less HDLSMALL). The benefits of omega-3 were particularly significant in smokers and those with lower baseline content of EPA and DHA. It was also observed that omega-9, present in olive oil, had a positive impact on the size of LDL.

A Neuropatia autonômica cardiovascular (NAC), apesar de ter sido apontada como fator de risco independente para doença cardiovascular (DCV) em pacientes com diabetes tipo 1 (DM1), permanece subdiagnosticada. Os objetivos do trababalho foram determinar a prevalência de NAC e seus indicadores clínicos e laboratoriais em pacientes com DM1 e a associação com outras complicações crônicas do diabetes, além de avaliar a concordância entre os critérios diagnósticos da NAC determinados pelos parâmetros da análise espectral e pelos testes reflexos cardiovasculares. Pacientes com DM1, duração da doença &#8805; 5 anos e com idade &#8805; 13 anos foram submetidos a um questionário clínico-epidemiológico, a coleta de sangue e de urina para determinação da concentração urinária de albumina, ao mapeamento de retina, e exame clínico para pesquisa de neuropatia diabética sensitivo motora além da realização de testes reflexos cardiovasculares. Cento e cinquenta e um pacientes com DM1, 53.6 % do sexo feminino, 45.7% brancos, com média de idade de 33.4 13 anos, idade ao diagnóstico de 17.2 9.8 anos, duração de DM1 de 16.3 9.5 anos, índice de massa corporal (IMC) de 23.4 (13.7-37.9) Kg/m2 e níveis de hemoglobina glicada de 9.1 2% foram avaliados. Após realização dos testes para rastreamento das complicações microvasculares, encontramos neuropatia diabética sensitivo motora, retinopatia diabética, nefropatia diabética e NAC em 44 (29.1%), 54 (38%), 35 (24.1%) e 46 (30.5%) dos pacientes avaliados, respectivamente. A presença de NAC foi associada com idade (p=0.01), duração do DM (p=0.036), HAS (p=0.001), frequência cardíaca em repouso (p=0.000), HbA1c (p=0.048), uréia (p=0.000), creatinina (p=0.008), taxa de filtração glomerular (p=0.000), concentração urinária de albumina (p=0.000), níveis séricos de LDL-colesterol (p=0.048), T4 livre (p=0.023) e hemoglobina (p=0.01) e a presença de retinopatia (p=0.000), nefropatia (p=0.000) e neuropatia diabética sensitivo motora (p=0.000), além dos seguintes sintomas; lipotimia (p=0.000), náuseas pós alimentares (p=0.042), saciedade precoce (p=0.031), disfunção sexual (p=0.049) e sudorese gustatória (p=0.018). No modelo de regressão logística binária, avaliando o diagnóstico de NAC como variável dependente, foi observado que apenas a FC em repouso, presença de neuropatia diabética sensitivo motora e retinopatia diabética foram consideradas variáveis independentes significativamente. A NAC é uma complicação crônica comum do DM1, atingindo cerca de 30% dos pacientes estudados e encontra-se associada à presença de outras complicações da doença. Indicadores da presença de NAC nos pacientes avaliados incluíram a idade, duração do diabetes, presença de HAS, frequência cardíaca de repouso e presença de sintomas sugestivos de neuropatia autonômica. O presente estudo ratifica a importância do rastreamento sistemático e precoce desta complicação. / The cardiovascular autonomic neuropathy (CAN), although considered as an independent risk factor for cardiovascular disease (CVD) in both patients with type 1 diabetes (T1D), remains underdiagnosed. The objective were to determine the prevalence, clinical and laboratorial indicators of CAN in patients with T1D and its association with other chronic complications of diabetes and evaluate the concordance between the diagnostic criteria for CAN diagnosis determined by the parameters of spectral analysis and the cardiovascular reflex tests. Patients with T1D aged &#8805; 13 years and diabetes duration &#8805; 5 years underwent a clinical-epidemiological survey, had blood samples collected, urinary samples for the determination of urinary albumin concentration, ophtalmoscopic exam, clinical neurological examination for diabetic neuropathy screeening and cardiovascular reflex tests. One hundred and fifty one patients with T1D, 53.6 % female, 45.7% Caucasian, mean age of 33.4 13 years, age at diagnosis of 17.2 9.8 years, diabetes duration of 16.3 9.5 years, body mass index (BMI) of 23.4 (13.7-37.9) kg/m2, glycated hemoglonin levels of 9.1 2% were evaluated. After performing the tests for screening for microvascular complications, we found diabetic sensory motor neuropathy, diabetic retinopathy, diabetic nephropathy and CAN in 44 (29.1%), 54 (38%), 35 (24.1%) and 46 (30.5%) of the patients, respectively. CAN was associated with age (p=0.01), diabetes duration (p=0.036), hypertension (p=0.001), resting heart rate (p=0.000), HbA1c (p=0.048), urea (p=0.000), creatinine (p=0.008), glomerular filtration rate (p=0.000), urinary albumin concentration (p=0.000), LDL-cholesterol (p=0.048), free T4 (p=0.023), hemoglobin (p=0.01) and presence of retinopathy (p=0.000), nephropathy (p=0.000) and diabetic neuropathy (p=0.000), the following symptons syncope (p=0.000), post prandial nausea (p=0.042), early saciety (p=0.031), sexual dysfunction (p=0.049) and gustatory sweating (p=0.018). In binary logistic regression model evaluating the diagnosis of CAN as a dependent variable, it was observed that only resting heart rate, presence of diabetic neuropathy and retinopathy were considered independent variables significantly. CAN is a common chronic complication of T1D affecting about 30% of the studied population and is associated with the presence of other chronic complications of T1D. Indicators of the presence of CAN included age, duration of diabetes, presence of hypertension, resting heart rate and symptoms suggestive of autonomic neuropathy. This study confirms the importance of systematic and early screening for this complication.

Dados recentes indicam uma relação inversa entre doença cardiovascular e consumo de flavonóides. O objetivo do estudo foi identificar parâmetros clínicos e vasculares de pacientes hipertensos tratados que apresentaram efeitos benéficos na função vascular após o consumo de chocolate amargo com 70% de cacau por sete dias. Vinte e um pacientes hipertensos em tratamento medicamentoso, ambos os sexos, com idades entre 40-65 anos, foram incluídos em um ensaio clínico intervencional com aferição de pressão arterial, dilatação mediada por fluxo braquial (DMF), tonometria arterial periférica (EndoPAT) e parâmetros hemodinâmicos centrais pelo SphygmoCor. Após sete dias de consumo de chocolate amargo (70% cacau) 75g/dia, as avaliações clínica e vascular foram repetidas. Os pacientes foram divididos em dois grupos de acordo com a resposta da DMF em respondedores (que apresentaram melhora na DMF, n= 12) e não-respondedores (que não apresentaram melhora, n = 9). O grupo respondedor apresentou menor média de idade (54 7 vs 61 6 anos, p = 0,037) e menor risco cardiovascular pelo escore de Framingham (2,5 1,8 vs 8,1 5,1%, p = 0,017). Além disso, os pacientes respondedores apresentaram valores mais baixos de pressão de pulso tanto periférica (55 9 vs 63 5 mmHg, p = 0,041), quanto central (44 10 vs 54 6, p = 0,021) quando comparado ao grupo não respondedor. A resposta da DMF apresentou correlação moderada e negativa com o escore de Framingham (r = -0,60, p = 0,014), com a DMF basal (r = 0,54, p = 0,011), com o índice de hiperemia reativa basal (IHR) obtido pelo EndoPAT (r = -0,56, p = 0,008) e com a pressão de pulso central (r = -0,43, p = 0,05). No entanto, após análise de regressão linear, apenas o escore de Framingham e o IHR basal foram associados com a resposta da DMF. Em conclusão, nesta amostra de pacientes hipertensos tratados, os indivíduos que apresentaram melhora da função endotelial com o consumo de chocolate amargo com 70% de cacau também mostraram redução da pressão arterial tanto sistólica como diastólica, eram mais jovens e tinham menor pressão de pulso e menor risco cardiovascular, apesar de uma disfunção endotelial basal / Recent findings indicate an inverse relationship between cardiovascular disease and consumption of flavonoids. We aimed to identify clinical and vascular parameters of treated hypertensive patients who present beneficial effects of dark chocolate on vascular function. Twenty-one hypertensive patients in drug therapy, both genders, aged 40-65 years, were included in a prospective study with measurement of blood pressure, brachial flow-mediated dilatation (FMD), peripheral arterial tonometry (EndoPAT) and central hemodynamic parameters by SphygmoCor. After seven days of eating dark chocolate (70% cocoa) 75g/day, the clinical and vascular evaluation were repeated. Patients were divided into two groups according to the response in FMD: responders (increase in FMD, n=12) and non-responders (no improvement in FMD, n=9). The responder group had a lower mean age (547 vs 616 years, p=0.037) and cardiovascular risk by Framingham score (2.51.8 vs 8.15.1 %, p=0.017). Moreover, responders patients presented lower values of both peripheral (559 vs 635 mmHg, p=0.041), and central pulse pressure (4410 vs 546, p=0.021) than those in non-responder group. The FMD response showed moderate and negative correlation with Framingham score (r= -0.60, p=0.014), with baseline FMD (r= 0.54, p=0.011), baseline reactive hyperemia index (RHI) by EndoPAT (r= -0.56, p=0.008) and central pulse pressure (r= -0.43, p=0.05). However, after linear regression analysis, only the Framingham score and baseline RHI were associated with FMD response. In conclusion, this sample of treated hypertensive patients, individuals who showed improvement in endothelial function with the consumption of dark chocolate with 70% cocoa also showed reduction in both systolic and diastolic blood pressure, were younger and had lower pulse pressure and lower cardiovascular risk, although a basal endothelial dysfunction

Durante a transição menopausal e a pós-menopausa cerca de 75% das mulheres apresentam sintomas de hipoestrogenismo, tais como fogachos. O emprego de terapia hormonal (TH) para alívio dos sintomas da menopausa está bem estabelecido, mas seus efeitos cardiovasculares (CV) permanecem controversos. Dados de estudos recentes indicam a presença de duas populações distintas quanto aos efeitos CV da TH. Essa diferenciação estaria relacionada principalmente com a idade e o tempo de pós-menopausa. Evidências sugerem também que a presença de fatores de risco cardiovascular antes do início do TH, ou de uma associação de fatores de risco, podem ser determinantes dos efeitos CV do TH. Dose de medicação, via de administração e o tipo de progestogênio utilizado em associação com estrogênio para TH também vem sendo estudados como possíveis fatores relacionados ao impacto CV do TH. O presente trabalho é composto por: 1) Ensaio clínico randomizado, comparando os efeitos da via oral baixa dose e via não oral sobre variáveis relacionadas com risco CV em uma população de mulheres saudáveis na pósmenopausa recente; 2) Ensaio clínico randomizado, onde foram avaliados os efeitos da adição de progesterona natural micronizada ao estrogênio não oral durante TH em mulheres na pós-menopausa recente; e 3) Revisão sistemática e meta-análise, onde foram sistematicamente buscados todos os artigos com TH baixa dose que avaliassem os efeitos desta terapia sobre variáveis relacionadas com risco cardiovascular: peso, índice de massa corporal, pressão arterial, proteína C reativa e lipídios. Desenvolvemos ensaio clínico randomizado, cross-over, com objetivo de avaliar os efeitos de dois tipos de tratamento hormonal na menopausa: oral baixa dose, estradiol 1 mg e drospirenona 2 mg diário e não oral, estradiol 17 β gel 1.5 mg (ou nasal 300 mcg) diário e progesterona micronizada vaginal, 200 mg, 14 dias por mês, sobre peptídeo natriurético atrial, variáveis relacionadas com inflamação e função endotelial, perfil antropométrico e metabólico em mulheres na pós-menopausa recente e sem doença clínica evidente. 101 mulheres na pós-menopausa foram alocadas aleatoriamente para iniciar o TH por um dos dois grupos de tratamento: via oral baixa dose (n=50) ou via não oral (n=51). Todas as pacientes utilizaram ambos os TH de forma seqüencial. Após o primeiro período de 2 a 3 meses de TH a paciente passava para o segundo tratamento, sem período de washout. A avaliação laboratorial foi realizada antes e após cada um dos tratamentos. A amostra do estudo foi composta por mulheres com média etária de 51 ± 3 anos e tempo de amenorréia de 22 ± 10 meses. Oitenta e seis pacientes concluíram o estudo. Peso e índice de massa corporal não se modificaram, enquanto que a circunferência da cintura reduziu de forma similar em ambos os grupos de tratamento. Colesterol total e LDL-C reduziram após ambos os TH, e triglicerídeos reduziram somente após a TH não oral. Insulina e glicemia de jejum não se modificaram. Não foram observadas modificações nos níveis de fibrinogênio, fator von Willebrand (FvW) e proteína C reativa (PCR) após TH oral. Após TH não oral, observou-se redução significativa de fibrinogênio e FvW. Níveis de PCR não se modificaram. Houve redução do número de pacientes no maior tertil de PCR (alto risco CV) após TH não oral. Essas pacientes passaram a integrar os grupos de risco intermediário e baixo. Níveis de peptídeo natriurético atrial (PNA) mantiveram-se inalterados após os ambos os TH. Não houve modificações significativas na pressão arterial e esta não se correlacionou com valores de PNA. Realizamos análise adicional do TH não oral, quanto às diferenças entre a via nasal e a percutânea e quanto aos efeitos da adição de progesterona natural micronizada ao estrogênio. Não houve diferenças significativas para todas as variáveis estudadas entre a via nasal e a via percutânea. A adição de progesterona natural micronizada não modificou os efeitos metabólicos e CV do estrogênio não oral. Foi realizada busca sistemática de todos os artigos que incluíssem como TH estrogênio baixa dose e avaliassem os efeitos deste tratamento sobre as variáveis de interesse: peso, índice de massa corporal, pressão arterial, proteína C reativa e lipídeos. Foram consultadas as bases MEDLINE, Cochrane CENTRAL, EMBASE. Foram revisadas todas as referências dos artigos de interesse e revisões e metaanálises no assunto, em busca de artigos relevantes. Após exclusão dos artigos em duplicata, 8610 artigos foram revisados. Destes, 28 artigos foram selecionados para meta-análise. Desta análise foi possível concluir que pacientes em uso de TH baixa dose apresentaram em média menor peso corporal, colesterol total e LDL-C do que não usuárias. A TH baixa dose não apresentou efeitos deletérios sobre demais variáveis estudadas. Em conclusão, ambos os TH apresentaram efeitos neutros ou benéficos sobre variáveis relacionadas com risco CV em uma população de mulheres na pósmenopausa recente e sem evidência de doença CV. A adição de progesterona natural micronizada não modificou os efeitos do estrogênio não oral. Os resultados da metaanálise sobre TH baixa dose e variáveis relacionadas com risco CV também permitem concluir que a TH baixa dose não exerceu efeitos deletérios sobre lipídeos e pressão arterial, e foi observado um possível efeito benéfico deste tratamento sobre o peso corporal. / During the menopausal transition and postmenopause about 75% of women have symptoms of hypoestrogenism symptoms such as hot flushes. The use of hormone therapy (HT) for relief of menopausal symptoms is well established, but its cardiovascular effects (CV) remain controversial. Data from more recent studies suggest the presence of two distinct populations regarding the cardiovascular effects of HT. This differentiation is related mainly to age and time after menopause. Evidence also suggests that the presence of cardiovascular risk factors before the onset of HT, or a combination of risk factors may be determinants of CV effects of HT. Medication dose, route of administration and type of progestin used in combination with estrogen for HT has also been studied as possible factors related to the CV impact of HT. This work consists of: 1) Randomized clinical trial, comparing the effects of low dose oral and non-oral route of variables related to CV risk in a population of healthy women in early postmenopausal; 2) A randomized clinical trial, which we assessed the effects of the addition of natural micronized progesterone to non-oral estrogen for HT in women in early postmenopausal; and 3) systematic review and meta-analysis, which were systematically searched all items with low-dose HT to assess the effects of this therapy on variables related to cardiovascular risk: weight, body mass index, blood pressure, C-reactive protein and lipids. A cross-over, randomized clinical trial was designed in order to evaluate the effects of two types of HT: low dose oral treatment, estradiol oral 1 mg and drospirenone 2 mg, by day and non-oral treatment, estradiol 1.5 mg 17 β gel by percutaneous route (or nasal route 300 mcg) by day and vaginal micronized progesterone, 200 mg/d, 14 days by month on atrial natriuretic peptide, variables associated with inflammation and endothelial function, anthropometric and metabolic variables on early and healthy postmenopausal women. One hundred one women were randomly allocated to start with one of the treatments: low dose oral treatment (n=50) or non-oral treatment (n=51). At the end the first three months period, the patients were crossed over without washout for an additional three months. Laboratory evaluated were carried before and after oral and non-oral HT. The sample of the study included postmenopausal women with a mean age of 51 years and duration of amenorrhea of 22±10 months. Eighty-six patients completed the study. Weight and body mass index remained unchanged, while the waist circumference decreased similarly in both treatment groups. Total cholesterol and LDL-cholesterol reduced after both the HT and triglycerides reduced only after nonoral HT. Insulin and fasting glucose did not change. No changes were observed in the levels of fibrinogen, von Willebrand factor (vWF) and C-reactive protein (CRP) after oral HT. After non-oral HT, there was a significant reduction of fibrinogen and vWF. CRP levels did not change. There was a reduction in the number of patients in the highest tertile of CRP (high CV risk) after non-oral HT. These patients have joined the groups of intermediate and low risk. Levels of atrial natriuretic peptide, ANP, were unchanged after both HT. There were no significant changes on blood pressure and did not correlate with values of ANP. We performed additional analysis of nonoral HT, for the differences between nasal and percutaneous and about the effects of addition of natural micronized progesterone to estrogen. There were no significant differences for all the variables studied between the nasal and percutaneously. The addition of micronized natural progesterone did not modify the metabolic and CV effects of non-oral estrogen. Systematic search of all articles that include as TH low dose estrogen and evaluate the effects of this treatment on the variables of interest was taken: weight, body mass index, blood pressure, C-reactive protein and lipids. The MEDLINE, Cochrane CENTRAL, EMBASE databases were consulted. All references of interest and reviews and meta-analyzes on the subject, in search of relevant articles were reviewed. After removing duplicate articles, 8610 articles were reviewed. Of these, 28 articles were selected for meta-analysis. From this analysis it was concluded that patients using low-dose TH had on average lower body weight, total cholesterol and LDL-C than non-users. The TH low dose showed no deleterious effects on other variables. In conclusion, low-dose oral and non-oral treatments had neutral or beneficial effects on variables related to CV risk in a population of women in early post menopausal and without evidence of CV disease. The addition of micronized natural progesterone did not modify the effects of non-oral estrogen. The results of the metaanalysis of low dose and TH variables related CV risk also showed that the TH low dose did not exert deleterious effects on lipids and blood pressure, and a possible beneficial effect of this treatment on body weight was observed.

L’objectif de ce travail de thèse était d’évaluer le bénéfice d’une activité physique régulière sur le syndrome d’apnées-hypopnées obstructives du sommeil (SAHOS). Pour répondre à notre objectif, cinq études ont été conduites pendant cette thèse et seront présentées au cours de ce manuscrit. Ces études se sont déroulées dans deux contextes de pratique distincts : un contexte associatif au sein de la Fédération Française d’Éducation Physique et de Gymnastique Volontaire (FFEPGV) et un contexte hospitalier au sein de l’Unité de réhabilitation cardio-respiratoire du CHU de Saint-Etienne. Notre étude principale, l’étude EXESAS, a évalué le bénéfice d’un programme d’activité physique pratiqué au sein de la FFEPGV (programme NeuroGyV™) dans une étude contrôlée randomisée incluant 96 patients avec un SAHOS modéré et âgés de 40 à 80 ans. Nous avons montré que neuf mois de ce programme, incluant trois heures d’activité physique par semaine, permettait de « guérir » 58% des patients du groupe exercice alors que seulement 20% des patients du groupe contrôle ayant bénéficié de conseils diététiques et de recommandations de bonne pratique en activité physique étaient considérés comme guéris (index d’apnées-hypopnées [IAH] < 15 évènements/heure). A l’issue du programme, les patients du groupe exercice amélioraient également leur qualité de vie et réduisaient leur somnolence. Au-delà de l’amélioration de l’IAH, nous avons mis en évidence une augmentation de la consommation maximale d’oxygène, suggérant une réduction du risque cardiovasculaire. L’étude EXESAS s’est par ailleurs intéressée à l’effet du programme NeuroGyV™ sur l’activité du système nerveux autonome (SNA) mesurée par la variabilité de fréquence cardiaque (VFC). Il a été montré que l’activité du SNA était préservée chez les patients SAHOS ayant bénéficié du programme d’activité physique. En revanche, le groupe contrôle présentait quant à lui une charge hypoxémique plus importante et une variabilité de fréquence cardiaque diminuée, suggérant que le SAHOS et le risque cardiovasculaire associé s’aggravaient spontanément en l’absence d’une activité physique régulière. Le screening de l’étude EXESAS a permis de réaliser un abstract sur le choix du questionnaire de dépistage du SAHOS le plus pertinent en population générale. Nous avons alors montré que le questionnaire STOP-BANG avait une meilleure sensibilité que le questionnaire de Berlin et qu’il devrait être privilégié en dépistage clinique même si sa spécificité reste faible.Enfin, nos travaux de recherche en réhabilitation cardiaque ont permis de confirmer le bénéfice du réentrainement à l’effort sur la sévérité du SAHOS et le rééquilibrage du SNA chez des patients coronariens. Par contre, les résultats préliminaires de l’étude RICAOS ont révélé que le renforcement des muscles inspiratoires chez les patients coronariens souffrant d’un SAHOS modéré n’apportait pas de bénéfice supplémentaire par rapport à un programme de réhabilitation cardiaque classique.En conclusion, l’activité physique régulière réduit efficacement la sévérité du SAHOS chez des patients avec ou sans antécédents cardiaques. Les résultats des différentes études conduites au cours de cette thèse suggèrent que l’activité physique régulière devrait être considérée comme une pierre angulaire dans la prévention et dans la prise en charge des formes légères et modérées. De futurs études devraient être conduites afin d’explorer plus en détail les mécanismes physiologiques sous-jacents et déterminer quels patients doivent bénéficier en priorité de cette alternative thérapeutique. / The main purpose of this thesis was to assess the benefit of regular physical activity on obstructive sleep apnea (OSA). A total of five studies were conducted during this thesis and will be presented during this manuscript. These studies took place in two different practice settings: a community setting within the French Federation of Physical Education and Voluntary Gymnastics (FFEPGV) and an in-hospital setting into the Cardiopulmonary Rehabilitation Unit of the University Hospital of Saint-Etienne.Our main study, EXESAS, evaluated the benefit of a community physical activity program practiced within the FFEPGV (NeuroGyV™ program) in a randomized controlled trial including 96 patients aged from 40 to 80 years with moderate OSA. We demonstrated that nine months of NeuroGyV™ program, including three hours of physical activity per week, could "cure" (apnea-hypopnea index [IAH] <15 events/hour) 58% of patients in the exercise group while only 20% of patients in the control group who received dietary advice and physical activity recommendations were considered cured. At the end of the program, patients in the exercise group also improved their quality of life and reduced their sleepiness. Beyond the improvement of the AHI, we demonstrated an increase in the maximum oxygen consumption during exercise test, suggesting a cardiovascular risk reduction.The EXESAS study also investigated the effect of the NeuroGyV™ program on autonomic nervous system (ANS) activity as measured by heart rate variability (HRV). We showed that ANS activity is preserved in OSA patients who benefited from the physical activity program. In contrast, patients in the control group had a greater hypoxemic load and decreased heart rate variability, suggesting that OSA and the associated cardiovascular risk worsened spontaneously in absence of regular physical activity.The screening of the EXESAS study led to an abstract on the choice of the most relevant OSA screening questionnaire in the general population. We showed that the STOP-BANG questionnaire had a better sensitivity than the Berlin and thus STOP-BANG questionnaire should be preferred in clinical screening even if its specificity remains low.Finally, our trial in cardiac rehabilitation confirmed the benefit of exercise training on OSA severity and on the rebalancing of ANS in coronary arterial disease (CAD) patients. Yet, preliminary results from the RICAOS study showed that inspiratory muscles training in CAD patients with moderate OSA do not provide additional benefits over a standard cardiac rehabilitation program.In conclusion, regular physical activity effectively reduces the severity of OSA in patients with or without a history of heart disease. The results of the five studies conducted during this thesis suggest that regular physical activity should be considered as a cornerstone in the prevention and management of mild and moderate forms.Future studies should be conducted to explore in more detail the underlying physiological mechanisms and determine which patients should better benefit from this therapeutic alternative as a matter of priority.

L'insuffisance rénale chronique (IRC) demeure un problème de santé publique du fait de l'augmentation de sa prévalence. Malgré l'amélioration de la prise en charge, le taux de mortalité reste plus élevé comparé à la population générale. Parmi les causes de décès, les maladies cardiovasculaires, d'origine multifactorielle (élargissement et hypertrophie des artères, athérosclérose, calcifications vasculaires et valvulaires) sont au premier plan. A côté des facteurs de risque classiques, des facteurs non traditionnels, liés aux perturbations métaboliques de l'IRC, ont été mis en évidence, comme l'inflammation, la malnutrition, le stress oxydant, les anomalies du métabolisme minéralo-osseux. La meilleure connaissance de la physiopathologie de la vasculopathie de l'IRC permet d'émerger de nouveaux biomarqueurs pour stratifier le risque cardiovasculaire chez l'IRC.OBJECTIFS-METHODOLOGIE GENERALE : Nous avons réalisé une approche biochimique pour explorer trois composantes du risque cardiovasculaire chez l'IRC : stress oxydant, perturbations qualitatives des HDL (high-density lipoprotein) et métabolisme minéralo-osseux.RESULTATS : Dans une première publication la production d'anion superoxyde a été évaluée, via une méthode de chemoluminescence, en fonction du stade de l'IRC. Alors que la surproduction de formes réactives de l'oxygène est bien connue au stade 5d et peut être liée à la procédure dialytique, il existe peu de données aux stades précoces. Notre étude a porté sur 136 patients IRC non dialysés des stades 1à 5. Les résultats montrent que la production de FRO est assurée aux stades 4 et 5. Un bas débit de filtration glomérulaire (MDRD<30ml/min/1.73m2), l'inflammation (fibrinogène >3.7g/l) et des taux anormaux d' HDL (<1.42mM et >1.75mM) apparaissent comme les principaux déterminants du stress oxydant chez l'IRC non dialysé.Alors que dans la population générale, un taux bas de HDL est reconnu comme un facteur de risque important, nous avons montré (publication 1) que des taux anormaux de HDL, bas comme hauts, étaient indépendamment associés au stress oxydant chez les sujets IRC. Dans une deuxième publication, nous avons précisé la composition des HDL en se basant sur d'éventuelles modifications qualitatives des protéines associées à la structure des lipoprotéines. Une étude protéomique a été réalisée chez 7 patients hémodialysés versus 7 sujets sains. Nous avons retrouvé 40 protéines exprimées différemment sur les 122 identifiées, dont l'apoCII, l'apoCIII qui sont significativement augmentées et la transferrine abaissée. Ces protéines interviennent dans de nombreuses fonctions comme la réponse inflammatoire, l'activation du complément, la régulation de l'oxydation des lipoprotéines, l'homéostasie des cations.Dans une troisième publication, l'épuration du FGF23, phosphatonine impliquée dans les anomalies du métabolisme minéralo-osseux, été étudiée chez l'hémodialysé chronique en fonction de la techniques de dialyse (hémodialyse (HD) high flux versus hémodiafiltration on line (OL-HDF)). Notre étude a porté sur 53 patients dans le groupe HD et 32 patients dans le groupe OL-HDF. Dans les deux groupes le taux de FGF23 en post-dialyse est significativement plus bas qu'en pré-dialyse. Cependant, le taux de réduction, la clairance et le KT/V du FGF23 sont significativement plus bas dans le groupe OL-HDF.CONCLUSION-PERSPECTIVES : Chez l'IRC, avec l'appariation de facteurs de risque non traditionnels, de nouveaux biomarqueurs ont émergés dans la stratification du risque cardio-vasculaire. Ces biomarqueurs peuvent devenir des bioacteurs et représenter de nouvelles cibles d'action et de prévention de l'atteinte cardio-vasculaire chez l'IRC. La complexité des mécanismes physiopathologiques impliqués, nous incite à proposer des approches multimarqueurs. Actuellement des études biocliniques se poursuivent en mettant en place des cohortes régionales de patients aux stades 1 à 5 et de patients incidents en dialyse. / BACKGROUND: Chronic kidney disease (CKD) is a public health problem because of its increasing prevalence. Despite care improvements, the mortality rate remains higher compared to general population. Among causes of death, cardiovascular diseases with multifactorial origins (enlargement and hypertrophy of arteries, atherosclerosis, vascular and valvular calcifications) are in the foreground. Besides the traditional risk factors, non-traditional factors associated with metabolic disorders in CKD were bring out, such as inflammation, malnutrition, oxidative stress, mineral and bone disorder. A better knowledge of vasculopathy physiopathology in CKD allows the emergence of new biomarkers to stratify cardiovascular risk in CKD.AIMS-METHODOLOGY: We performed a biochemical approach to explore three components of cardiovascular risk in CKD: oxidative stress, qualitative alterations of HDL (high-density lipoprotein) and mineral and bone disorder.RESULTS: In a first publication, the superoxide anion production, according to the stage of CKD, was assessed using a chemiluminescence method. While the overproduction of reactive oxygen species is well known at the 5d stage of CKD and may be related to the dialysis procedure, there are few data in the early stages. Our study included 136 non-dialysis patients at stages 1 to 5 of CKD. Results showed an enhanced superoxide production at the pre-dialysis phase, stages 4 and 5 of CKD. Reduced glomerular filtration rate (MDRD <30 ml / min / 1.73m2), inflammation (fibrinogène≥3.7g / l) and abnormal levels of HDL (<1.42mM and ≥1.75mM) appears as main determinants of oxidative stress in non-dialysis CKD patients.While in general population, a low HDL rate is recognized as an important risk factor, we showed (publication 1) that abnormal levels of HDL, low as high, were independently associated with oxidative stress in CKD subjects. In a second publication, we have defined the HDL composition based on qualitative changes in the structure of proteins associated with lipoproteins. A proteomic study was performed in 7 patients on hemodialysis versus 7 healthy subjects. We found 40 proteins differently expressed on the 122 identified, including apoCII, apoCIII which are significantly increased and transferrin lowered. These proteins are involved in many functions such as inflammatory response, complement activation, regulation of lipoprotein oxidation and homeostasis cations. In a third publication, the removal of FGF23, phosphatonin involved in mineral and bone metabolism, was studied in chronic hemodialysis according to the dialysis techniques (high flux hemodialysis (HD) versus on line hemodiafiltration (OL- HDF)). Our study included 53 patients in the HD group and 32 patients in the OL-HDF group. In both groups the rate of FGF23 in post-dialysis was significantly lower than in pre-dialysis. However, rate of reduction, clearance and KT / V of FGF23 were significantly lower in the OL-HDF group.CONCLUSION-PROSPECTS: In the IRC, with the appearance of non traditional risk-factors, new biomarkers have emerged in the stratification of cardiovascular risk. These biomarkers can become bioactors and represent novel targets of action and prevention in the cardiovascular disease in CKD. The complexity of the involved physiopatholological mechanisms, leads us to propose multimarkers approaches. Currently bioclinical studies continue with the constitution of regional cohorts of patients at stages 1 to 5 of CKD and incident dialysis.

Heart rate varies constantly as a consequence of activity in the sympathetic and parasympathetic autonomic nervous systems (SNS and PNS). In short-term recordings, heart rate variability (HRV) is mostly related to the inhibitory activity of the vagal nerves, which are part of the PNS. HRV is lower when under stress as well as in several illnesses and psychiatric conditions. Decreased HRV is also related to cardiac disease, which is the leading cause of death worldwide. Autonomic imbalance, measured as HRV, is suggested as a mediator between psychosocial distress and cardiovascular disease. The aim of the present thesis was to investigate the connection between HRV and psychosocial distress, including psychiatric problems (studies I and II), and lifestyle factors (study III). In study I, additional physiological measures sensitive to autonomic activity and results from a continuous attention test were investigated in parallel with HRV. In studies II and III the participants were adolescents. The results show that HRV is lower in women with stress-related fatigue and adolescent girls with a psychiatric diagnosis compared to healthy control groups. However, these groups did not exhibit an increase in physiological measures of SNS origin, which supports the assumption that the observed hyperarousal is related to decreased vagal activity rather than increased SNS activity. Women with stress-related fatigue made more impulsive errors and had a “risky” response style in the continuous attention test. There was a negative correlation between test performance and HRV. Decreased vagal activity is thus associated with deficient behavioural inhibition. In study III, HRV in a group of healthy adolescent boys and girls was positively associated with physical activity but not with other lifestyle measures. Even at young age HRV is a sensitive marker of autonomic imbalance resulting from psychosocial stress. Future longitudinal research will show whether HRV can be used for early identification of people at risk of cardiovascular disease and whether such interventions will lower the risk of cardiac morbidity.

Objectives and methods: DETECT is a cross-sectional study of 55,518 unselected consecutive patients in 3188 representative primary care offices in Germany. In a random subset of 7519 patients, an extensive standardized laboratory program was undertaken. The study investigated the prevalence of cardiovascular disease, known risk factors (such as diabetes, hypertension and dyslipidemia and their co-morbid manifestation), as well as treatment patterns. The present analysis of the DETECT laboratory dataset focused on the prevalence and treatment of dyslipidemia in primary medical care in Germany. Coronary artery disease (CAD), risk categories and LDL-C target achievement rates were determined in the subset of 6815 patients according to the National Cholesterol Education Program (NCEP) ATP III Guidelines. Results: Of all patients, 54.3% had dyslipidemia. Only 54.4% of the NCEP-classified dyslipidemic patients were diagnosed as ‘dyslipidemic’ by their physicians. Only 27% of all dyslipidemic patients (and 40.7% of the recognized dyslipidemic patients) were treated with lipid-lowering medications, and 11.1% of all dyslipidemic patients (41.4% of the patients treated with lipid-lowering drugs) achieved their LDL-C treatment goals. In conclusion, 80.3% of patients in the sample with dyslipidemia went undiagnosed, un-treated or under-treated.